By Marie Rosenthal
More than 97% of people with migraine will use acute medication to manage an attack, according to Dawn C. Buse, PhD, a clinical professor of neurology at Albert Einstein College of Medicine, in New York City.
This statistic might change with the FDA approval of erenumab-aooe (Aimovig, Amgen/Novartis), a medication in a new class of drugs to prevent migraine in adults, which Dr. Buse called a “paradigm shift” in managing migraine. Erenumab-aooe is the first